# Scottish Widows Investment Partnership

> Scottish Widows Investment Partnership is a VC fund backing Therapeutics. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Edinburgh, United Kingdom
- Total investments: 5
- Last investment: May 2024
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.swip.com

Scottish Widows Investment Partnership is a VC fund in Edinburgh focused on Therapeutics and Biotechnology. Scottish Widows Investment Partnership – SWIP – is one of the largest asset management companies in Europe. Their teams are recognised as high fliers within the industry. Their performance is based on their skills, backed by thorough research, and the ability to uncover and capitalise on opportunities as soon as they arise.They invest across allasset classes, including equities, property, bonds and cash. They also offer specialist expertise in multi-manager and multi-asset solutions.Their goal: to provide superior risk-adjusted returns and quality service for their clients, which include individuals, pension funds, charities and financial institutions from around the world.Whatever your investment requirements, their teams have the innovation, drive and skill to deliver investment solutions that perform.

## Contacts

5 contacts available for Scottish Widows Investment Partnership. Shizune tracks 5 team members at Scottish Widows Investment Partnership. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/scottish-widows-investment-partnership?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 40% |
| Biotechnology | 2 | 40% |
| Health Care | 1 | 20% |
| Pharmaceutical | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 2 | 40% |
| Series C | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew November | Director of Investment Propositions | 0 | https://shizune.co/investors/profile/andrew-november |
| Francis Ghiloni | Director of Distribution & Client Management | 0 | https://shizune.co/investors/profile/francis-ghiloni |
| Sean Phayre | Head of Quantitative Investments | 0 | https://shizune.co/investors/profile/sean-phayre |
| Tony Owens | Director of Operations, Strategy & Finance | 0 | https://shizune.co/investors/profile/tony-owens |
| William Low | Director | 0 | https://shizune.co/investors/profile/william-low |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zenobe Energy | Zenobe Energy ( formerly known as Battery Energy Storage Solutions Limited) is the largest independent owner and operator of battery storage in the UK. We transform the way grid operators and businesses use power to reduce costs, improve reliability and benefit the environment. | $520.6M | Debt Financing | May 29, 2024 |  |
| Cara Therapeutics | Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $15M | Series D | Jul 21, 2010 |  |
| Cara Therapeutics | Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $24M | Series C | Nov 28, 2006 |  |
| ARYx Therapeutics | ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease. | $30.4M | Series E | Feb 10, 2006 |  |
| ARYx Therapeutics | ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease. | $55M | Series D | Jun 01, 2004 |  |

5 of 5 investments shown.

## Co-investors
- [Ascent Biomedical Ventures](https://shizune.co/investors/profile/ascent-biomedical-ventures) — VC Fund, 3 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 2 deals together
- [Jafco Life Science](https://shizune.co/investors/profile/jafco-life-science) — VC Fund, 2 deals together
- [Merlin Biomed](https://shizune.co/investors/profile/merlin-biomed) — VC Fund, 2 deals together
- [Montreux Equity Partners](https://shizune.co/investors/profile/montreaux-equity-partners) — VC Fund, 2 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Scottish Widows Investment Partnership invest in?

Scottish Widows Investment Partnership invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Series D and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Scottish Widows Investment Partnership?

Public channels for Scottish Widows Investment Partnership include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Scottish Widows Investment Partnership?

The team at Scottish Widows Investment Partnership includes Andrew November (Director of Investment Propositions), Francis Ghiloni (Director of Distribution & Client Management) and Sean Phayre (Head of Quantitative Investments). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co